contrast agent BR1: Clinical Trials

15 trials of contrast agent BR1, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 recruiting, 2 terminated, 2 unknown. 15 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 315Completed 6, Recruiting 4, Terminated 2, Unknown 2, Withdrawn 1

Follow contrast agent BR1: new trials by email Literature Review of contrast agent BR1 trials Research Report on contrast agent BR1

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Contribution of Contrast Enhanced Ultrasound for Diagnosis of Adnexal Torsion
Addition of ultrasound with contrast injection (SonoVue®), Standard Care (in control arm) - Adnexal Torsion
Phase 3RecruitingCentral Hospital, Nancy, France2562025-05-142026-04-08
Study of Placental Vascularization Using Contrast Ultrasound
SonoVue - Fetal Growth Restriction
Phase 3RecruitingCentral Hospital, Nancy, France302025-04-092026-04-07
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound - Glioblastoma Multiforme, Glioblastoma
Phase 3RecruitingNaviFUS Corporation322024-11-082026-04-09
Neonatal Brain Ultrasound With CEUS and Elastography
Brain contrast enhanced ultrasound, brain ultrasound elastography, Sulfur Hexafluoride - Neonatal Hypoxic Ischemic Encephalopathy, Neonatal Stroke
Phase 3RecruitingTurku University Hospital1002024-01-012026-01-15
Preterm Neonates Brain Ultrasound With CEUS and Elastography
Brain contrast enhanced ultrasound, brain ultrasound elastography, Sulfur Hexafluoride - Prematurity
Phase 3WithdrawnTurku University Hospital2024-01-012026-01-15
Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC
Sonovue and Sonazoid, Sonazoid and Sonovue - Hepatocellular Carcinoma, Cirrhosis
Phase 3UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine1002019-06-302019-09-19
Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)
SonoVue, Sodium chloride, Transcranial Ultrasound - Ischemic Stroke
Phase 3TerminatedUmeå University12017-11-282018-05-11
KVUS at Neoadjuvant CTx of Breast Cancer
SonoVue - Early Primary Breast Cancer
Phase 3UnknownRWTH Aachen University602016-12-122017-12-28
HexafluOride, a Contrast Agent for Placenta Echo-angiography
Contrast agent: SonoVue®. - Pregnancy
Phase 3CompletedCentre Hospitalier Régional Metz-Thionville552016-10-122026-06-24
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
Lumason - Coronary Artery Disease
Phase 3CompletedBracco Diagnostics, Inc1742015-10-122021-07-07
Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
sulphur hexafluoride lipid-type A microspheres - Heart Disease
Phase 3TerminatedBracco Diagnostics, Inc132015-10-012020-07-13
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
Lumason - Coronary Artery Disease
Phase 3CompletedBracco Diagnostics, Inc1752015-09-242021-06-11
An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging
Sonazoid™, SonoVue® - Liver Lesions
Phase 3CompletedGE Healthcare4242014-05-112018-10-31
IMaging Della PLAcca Carotidea
Visipaque 320 and SonoVue - Carotid Artery Plaque, Atherosclerosis
Phase 3CompletedEnrico Ammirati752012-04-012018-02-19
SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
SonoVue® - Liver Neoplasms
Phase 3CompletedBracco Diagnostics, Inc3532010-06-012018-08-03

Conditions studied

Coronary Artery Disease (2)  ·  Ischemic Stroke (2)  ·  Atherosclerosis (1)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carotid Artery Diseases (1)  ·  Carotid Stenosis (1)  ·  Fetal Growth Retardation (1)  ·  Fibrosis (1)  ·  Glioblastoma (1)  ·  Glioma (1)  ·  Heart Diseases (1)  ·  Liver Neoplasms (1)  ·  Neoplasms (1)

Sponsors

Bracco Diagnostics, Inc (4)  ·  Central Hospital, Nancy, France (2)  ·  Turku University Hospital (2)  ·  Centre Hospitalier Régional Metz-Thionville (1)  ·  Enrico Ammirati (1)  ·  GE Healthcare (1)  ·  NaviFUS Corporation (1)  ·  RWTH Aachen University (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  Umeå University (1)

Countries

United States (4)  ·  France (3)  ·  Canada (2)  ·  China (2)  ·  Finland (2)  ·  Germany (2)  ·  Taiwan (2)  ·  Belgium (1)  ·  Italy (1)  ·  South Korea (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Jussi Hirvonen (2)  ·  Melda Dolan, MD (2)  ·  Riitta Parkkola (2)  ·  Tiina Laurikainen (2)  ·  Vilhelmiina Parikka (2)  ·  Alberto Spinazzi, M.D. (1)  ·  Elias Johansson, MD, PhD (1)  ·  Elmar Stickeler, niv.-Prof. Dr. med. (1)  ·  Enrico Ammirati, Doctor (1)  ·  Francois Tranquart, MD, PhD (1)  ·  Melda Dolan, M.D. (1)  ·  Paolo G Camici, Professor (1)

Results publications

PMID 26777226, PMID 27751505, PMID 28874779, PMID 29432486, PMID 31101367, PMID 31511289, PMID 38401206

NIH funding

2023 (1)